Obecure intends to validate the safety and therapeutic potential of Histalean™ for weight management through Phase II clinical trials in obesity and psychosis treatment. 

Studies of the combined Histalean™ and Zyprexa® (olanzapine) treatment have been partially supported by a research grant from Eli Lilly, who have the right to view the research results.

For more advanced clinical studies, the company intends to seek partnerships and collaborations with major pharmaceutical companies that have established capacity in commercialization.